Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Reported profit after tax declined 19% year-on-year to Rs 76 crores
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
